MXC’s Derma division receives first purchase order with $8M deal

By Zoe Gross. Published at Nov 15, 2017, in Biotech

European-based specialist medicinal cannabis company, MGC Pharmaceuticals (ASX:MXC), has revealed some promising news relating to its MGC Derma division, marking its first material revenues.

MGC Derma has now received its first formal purchase order from Varm Cosmo for cannabidiol (CBD) cosmetic products under an $8 million binding sales agreement. These products will be sold to consumers as part of Varm Cosmo’s cosmetics range.

This comes bang on schedule, delivering as promised in MXC’s October announcement.

MGC Derma is a joint venture with widely recognised cosmetic manufacturer, Dr. M. Burstein Ltd, of which MXC owns 51 per cent and holds management control.

Varm Cosmo is a strongly backed, emerging Korean health care and beauty cosmetics company with a global distribution network, and sells its CBD range online and through a number of retail outlets.

This alliance is a major strategic entry point for MXC into the massive global cosmetics market.

The agreement is for a minimum contracted volume of $8 million of product. The MGC Derma products delivered will be marketed and sold by Varm Cosmo under a new premium brand, which will be launched in coming months.

Significantly, this initial purchase order wll deliver the first material revenues for MGC Derma within days, and forms part of the $1 million deposit, which is on track to be received in November.

However, those considering this stock shouldn’t make assumptions regarding future sales, nor should they base investment decisions on performances to date. Those considering this stock should seek independent financial advice.

Under the terms of the agreement, this first payment is to be paid to MGC Derma within five business days of the purchase order.

MXC is now in advanced stages of negotiation with Varm Cosmo for the two additional contracts, which will deliver MGC Derma products into new Varm Cosmo markets. These agreements are expected to close by both parties in the coming weeks to complete the full $40 million supply agreement.

This news puts MXC on a major high. The company is in a sound financial position, with $9.5 million cash in the bank and no debt, and is now entering its revenue phase at full throttle.

Roby Zomer, MXC co-founder and CEO, said “The receipt of the first purchase order signals a milestone for our company under what is a transformational deal that will not only deliver significant revenues but also provide a platform for MGC Derma to rapidly expand its presence in the global cosmetics market, which presents a very large opportunity for our company.”

“Furthermore, this milestone will generate additional revenue stream from our CBD extractions produced by our Pharma division.”

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.